Archive for the 'Crohns News' Category

Asacol 800mg MR Tablets Dosed At 4.8g/Day Herald Fast Symptom Relief And Improved Quality Of Life For reasonably Active UC Patients

Procter & Gamble Pharmaceuticals (NYSE: P&G) announced that Asacol(R) (mesalazine) 800mg Modified Release (MR) tablets are now available in the UK for the treatment of gentle to moderate acute exacerbations of ulcerative colitis (UC), and the maintenance of remission in UC and Crohn’s ileo-c…

FDA Approves Tysabri® For The Treatment Of Moderate-To-Severe Crohn’s Disease

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced the approval of a supplemental Biologics License Application (sBLA) by the U.S. Food and Drug Administration (FDA) for TYSABRI® (natalizumab).Original post by Dentistry News From Medical News Today

FDA Approves Tysabri To Treat Moderate-To-Severe Crohn’s Disease

The U.S. Food and Drug Administration has approved Tysabri (natalizumab) for the treatment of moderate-to-severe Crohn’s disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn’s disease therapies. Crohn’s disease patien…

Intestinal Inflammation Decreased By Il-22 Gene

There are two major types of inflammatory bowel disease (IBD), Crohn disease (CD) and ulcerative colitis (UC). Conflicting reports have indicated that the soluble factor IL-22 can have both IBD promoting and IBD controlling effects. But now, Atsushi Mizoguchi and colleagues at Massachusetts General …

Scientists Find How Bacteria In Cows’ Milk May Cause Crohn’s Disease

Scientists at the University of Liverpool have found how a bacterium, known to cause illness in cattle, may cause Crohn’s disease in humans. Crohn’s is a condition that affects one in 800 humans in the UK and causes chronic intestinal inflammation, main to pain, bleeding and diarrhoea.The team fou…

Milk and Crohn’s: A connection?

Breakthrough research has come up with a startling discovery in the world of health — there’s a very strong connection amoung milk and Crohn’s disease. More specifically, a bacteria in milk has apparently been shown to lead to Crohn’s disease, according to that scoop from The Daily Mail.

For…

Bacteria In Cows’ Milk May Cause Crohn’s Disease

Crohn’s is a condition that affects one in 800 society in the UK and causes chronic intestinal inflammation, main to pain, bleeding and diarrhoea.The team found that a bacterium called Mycobacterium paratuberculosis releases a molecule that prevents a type of white blood cell from killing E.coli bac…

Differing Physician And Patient Perceptions Regarding affect Of UC Revealed by Nationwide Survey

Nearly three out of four patients with ulcerative colitis (UC) consider feeling unwell to be a normal part of life, while gastroenterologists estimate that to be true for only 37 percent of their UC patients, according to results from a nationwide series of surveys presented at the 2007 Crohn’s &amp…

Callisto Announces Presentation On Guanilib At 2007 Crohn’s And Colitis Foundation National Research And Clinical Conference

Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal diseases, announced that Dr. Kunwar Shailubhai, Sr. VP Discovery Research, will give an oral presentation covering preclinical input on Guanilib at the Crohn’s an…

CHMP Adopts Negative Opinion On Appeal On European Application For Natalizumab For The Treatment Of Crohn’s Disease

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion on the marketing authorization for natalizumab as a treatment fo…

UCB To Appeal European Negative Opinion On CIMZIA(R) For The Treatment Of Patients With Crohn’s Disease

UCB announced that it has been informed by the European Medicines Agency (EMEA) that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the market authorisation application (MAA) in the EU for CIMZIA(R) certolizumab pegol) in the treatment of patients with …

Next Page »